Intravesical bacillus calmette-guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours

Oncology (Switzerland)

Volumn 53, Issue 4, 1996, Pages 281-288

  Melekos, Michael D ^a   Zarakovitis, Ioannis E ^a   Fokaefs, Eleftherios D ^a   Dandinis, Kosmas ^a   Chionis, Heracles ^a   Bouropoulos, Constantinos ^a   Dauaher, Hussam ^b  

^a University Hospital Rio   (Greece)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

BCG Epirubicin; Bladder cancer; Transitional cell

Indexed keywords

BCG VACCINE; EPIRUBICIN; ETOGLUCID; MITOMYCIN C; THIOTEPA;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; FEMALE; FEVER; HEMATURIA; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTICARCINOGENIC AGENTS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; HUMANS; MALE; MYCOBACTERIUM BOVIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 0029975311     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227574     Document Type: Article

References (34)

1. Herr HW, Laudone VP. Whitmore WF Jr: An overview of intravesical therapy for superficial bladder tumors. J Urol 1987; 138; 1363-1368.
2. Soloway MS: Diagnosis and management of superficial bladder cancer. Semin Surg Oncol 1989;5:247-254.
3. Lamm DL, Griffith G, Pettit LL, Nseyo UO: Current perspectives on diagnosis and treatment of superficial bladder cancer. Urology 1992:39:301-308.
4. Ploskcr GL, Fauld D: Epirubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993:45:788-856.
5. Calais da Silva F, Perrito F, Brandao T, Santos A: 4'-epi-doxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. Eur Urol 1992:21:42-44.
6. Mclekos MD, Dauaher H, Fokacfs ED, Barbabas G: Intravesical instillation of 4'-epi-doxo-rubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol 1992:147: 371-375.
7. Melekos MD: Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. Oncology 1993:50: 450-455.
8. Oosterlinck W, Kurth KH, Schröder F, Bultnick J. Hammond B, Sylvester R and Members of the EORTC Genitourinary Group: A prospective EORTC Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta. Tl papillary carcinoma of the bladder. J Urol 1993:149:749-752.
9. Martinez-Pineiro JA, Jimenez-Leon JS, Marti-nez-Pinciro L Jr, Fiter L, Mosteiro JA, Navarro J, Garcia Matres MJ, Carcamo P: Bacillus Cal-metle-Gucrin versus doxorubicin versus thio-tcpa: A randomized prospective study in 202 patients w ith superficial bladder cancer. J Urol 1990:143:502-506.
10. Herr HW: Transurethral resection and intravesical therapy of superficial bladder tumors. Urol Clin N Am 1991:18:525-528.
11. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Criss-man JD, Coltman CA: A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 1991:325:1205-1209.
12. Brosman SA: Bacillus Calmette-Guerin immunotherapy. Urol Clin N Am 1992;19:557-564.
13. Heney NM, Ahmed S, Flanagan M, Krable W, Corder M, Hafermann MD, and Hawkins IR for the National Bladder Collaborative Group A: Superficial bladder cancer: Progression and recurrence. J Urol 1983:130:1083-1086.
14. Cutler SJ, Ederer F: Maximum utilization of the life table method in analyzing survival. J ChronDis 1958:8:699-752.
15. Melekos MD, Chionis H, Pantazakos A, Fokacfs ED, Paranychianakis G, Dauaher H: Intravesical bacillus Calmette-Guerin immuno-prophylaxis of superficial bladder cancer: A controlled prospective trial with a modified treatment schedule. J Urol 1993:149:744-748.
16. Vegt PDJ, Witjes JA, Witjes WPJ, Doesburg WH, Debruync FMJ, van der Meijden APM: A randomized study of intravesical mitomycin C. bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin R1VM treatment in pTa-pTl papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995:153:929-933.
17. Riibben H, Lutzeyer W, Fisher N, Deutz F, Lagrange W, Gianni G: Natural history and treatment oflow and high risk superficial bladder tumors. J Urol 1988;139:283-285.
18. Melekos MD, Chionis HS, Paranychianakis GS, Dauaher HH: Intravesical 4'-epi-doxorubi-cin (epirubicin) versus bacillus Calmettc-Guc-rin: A controlled prospective study on the prophylaxis of superficial bladder caner. Cancer 1993;72:1749-1755.
19. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Boecken Kruger C, dePauw M, Sylvester R and Members of the EORTC Genitourinary Group: Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Results of 2 EORTC randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillation and short-term versus long-term treatment. J Urol 1995:153: 934-941.
20. Soloway MS, Jordan AM, Murphy WM: Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transi-tional-cell carcinoma: in Debruyne FMJ. Denis L. van der Meijden APM (eds): BCG in Superficial Bladder Cancer. New York. Liss, 1989. pp 215-236.
21. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WE Jr, Fair WR, Oettgen HF: A prospective randomized trial of maintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. Clin Oncol 1987:5:441-449.
22. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ: Single course versus maintenance bacillus Calmette-Gucrin therapy for superficial bladder tumors: A prospective randomized trial. J Urol 1987:138:295-298.
23. Flamm J: Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol 1990;17:119-124.
24. Kavoussi LR. Torrence RJ. Gillen DP. Hudson M'L A. Haaff EO. Dresner SM. Ratliff TL. Catalona WJ: Results of six weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors. J Urol 1988:139:935-940.
25. Melekos MD, Pantazakos A, Markou S, Skopa C, Alhanassopoulos A, Barbalias G: Intravesical bacillus Calmette-Guerin administration in the prophylaxis of superficial bladder cancer. Int Urol Nephrol 1990:22:433-440.
26. Herr HW, Wartinger DD, Fair WR, Oettgen HF: Bacillus Calmette-Gucrin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 1992;147:1020-1023.
27. Nadler RB, Catalona WJ, Iludson MA, Ratliff TL: Durability of the tumor-free response for intravesical bacillus Calmette-Guérin therapy. J Urol 1994:152:367-373.
28. Ratliff TL, Catalona WJ: Depressed proliferative responses in patients treated with 12 weeks of intravesical BCG. Part 2 (abstract 244). J Urol 1989;144:230A.
29. Lamm DL: BCG in perspective: Advances in the treatment of superficial bladder cancer. Eur Urol 1995;27(suppl l):2-8.
30. Soloway MS, Perry A: Bacillus Calmette-Gue-rin lor the treatment of superficial transitionalcell carcinoma of the bladder in patients who have failed thiotcpa and/or mitomycin C. J Urol 1987:137:871-873.
31. Herr HW, Badalament RA, Amato DA, Lau-done VP, Fair WR, Whitmore WF Jr: Superficial bladder cancer treated with bacillus Cal-mettc-Guerin: A multivariate analysis of factors affecting tumor progression. J Urol 1989: 141:22-29.
32. Meekos MD: Intravesical bacillus Calmette-Gucrin prophylactic treatment for superficial bladder tumors: Results of a controlled prospective study. Urol Int 1990:45:137-141.
33. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Carbaghlio A: A low-dose bacillus Calmette-Gucrin regimen in superficial bladder cancer therapy: Is it effective? J Urol 1991; 146:32-35.
34. Herr HW, Schwalb DM, Zhang ZF, Sogani PC, Fair WR, Whitmore WF Jr, Oettgen HF: Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995:13:1404-1408.